Catalog No.
Product Name
Application
Product Information
Citations
-
ADC Linker
Propargyl-PEG1-SS-PEG1-acid is a cleavable linker designed for use in antibody-drug conjugates (ADCs). This compound features an alkyne group enabling copper-catalyzed azide-alkyne cycloaddition (CuAAc), facilitating efficient conjugation with azide-containing molecules. Its unique structure and properties make it a valuable tool for researchers involved in the development of targeted therapeutics. -
ADC/PROTAC Linker
Propargyl-PEG6-NHS ester is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs) and PROTACs. This PEG-based reagent features an alkyne group that enables copper-catalyzed azide-alkyne cycloaddition (CuAAc), facilitating the conjugation of biomolecules. Its versatility as a click chemistry reagent enhances the development of targeted therapies in chemical biology and drug discovery applications. -
ADC Linker
Fmoc-N-(2-Boc-aminoethyl)-Gly-OH is a Fmoc-protected glycine derivative designed for use as a linker in antibody-drug conjugate (ADC) synthesis. This reagent facilitates the conjugation of antibodies with cytotoxic agents, enabling targeted delivery of therapeutic compounds. Its structural features make it suitable for various applications in bioconjugation and drug development research. -
ADC Linker
Fmoc-Hyp(Bom)-OH is a non-cleavable linker specifically designed for the synthesis of antibody-drug conjugates (ADCs). This compound features a unique structure that promotes effective conjugation while maintaining stability in biological systems. Additionally, Fmoc-Hyp(Bom)-OH can serve as an alkyl chain-based linker for the development of proteolysis-targeting chimeras (PROTACs), facilitating targeted protein degradation studies. Its versatile applications make it an essential tool for researchers in the fields of drug development and chemical biology. -
ADC Linker
DBCO-PEG3-acid is a non-cleavable ADC linker featuring a 3-unit polyethylene glycol (PEG) chain. Its primary mechanism involves the strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules, enabling effective conjugation in the synthesis of antibody-drug conjugates (ADCs). This reagent is particularly valuable in therapeutic research applications, facilitating targeted drug delivery and enhancing the pharmacological properties of antibody-based treatments. -
ADC Linker
PPC-NHS ester is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the conjugation of cytotoxic agents to antibodies, enabling targeted delivery and enhancing therapeutic efficacy. Its specific reactivity allows for the stable attachment of drugs while ensuring release under appropriate conditions, making it valuable for development in cancer therapeutics and targeted treatment strategies. -
ADC Linker
Docosanedioic acid functions as a non-cleavable linker in the development of antibody-drug conjugates (ADCs). Its elongated alkyl chain structure provides robust stability, making it suitable for conjugating therapeutic agents to antibodies. Additionally, this compound serves as an alkyl chain-based PROTAC linker, facilitating the synthesis of proteolysis-targeting chimeras (PROTACs) for targeted degradation in research applications. -
ADC/PROTAC Linker
Amino-PEG5-C2-acid is a PEG-based linker designed for use in the synthesis of PROTACs and non-cleavable antibody-drug conjugates (ADCs). This compound facilitates the conjugation of active pharmaceutical ingredients to antibodies, thereby enhancing target specificity and therapeutic efficacy. Its unique structure allows for optimal stability and performance in bioconjugation applications, making it a valuable tool for researchers in drug development and targeted therapy. -
ADC Linker
Mal-EGGGG-PEG8-amide-bis(deoxyglucitol) is a cleavable linker specifically designed for antibody-drug conjugate (ADC) applications. This compound enables the controlled release of therapeutic agents, enhancing the efficacy and specificity of targeted cancer treatments. Its structure facilitates stable conjugation while allowing for timely payload delivery upon internalization by target cells. Researchers can utilize this linker in the development of ADCs for improved tumor-targeting strategies in preclinical studies. -
Click Chemistry Reagent
H-L-Tyr(2-azidoethyl)-OH hydrochloride is an unnatural tyrosine derivative designed for use in click chemistry applications. Featuring an azide functional group, this reagent is suitable for copper-catalyzed azide-alkyne cycloaddition (CuAAc) with various alkyne-containing molecules. Additionally, it can facilitate ring strain-promoted alkyne-azide cycloaddition (SPAAC) in reactions involving DBCO or BCN groups, making it a versatile tool for bioconjugation and synthetic biology studies. -
ADC Linker
DBCO-PEG24-Maleimide is a versatile linker featuring a maleimide group and a DBCO (dibenzocyclooctyne) moiety. This compound is ideal for conjugating thiol-containing biomolecules and facilitates efficient click chemistry reactions with azide-bearing substrates. Its unique structure enables stable linkages, making it suitable for applications in antibody-drug conjugates (ADCs) and other bioconjugation frameworks in chemical biology research. -
Click Chemistry Reagent
Norbornene-NHS is a versatile click chemistry reagent targeting the site-specific conjugation of biomolecules. As a dienophile, it facilitates copper-free click reactions with tetrazines, enabling efficient and selective labeling and modification. This reagent is ideal for applications in bioconjugation, protein labeling, and the development of advanced materials in chemical research. -
ADC Linker
H-Asp-Gly-OH is a cleavable ADC linker that enables the selective delivery of therapeutic agents to target cells. This compound demonstrates effective release mechanisms under specific conditions, facilitating the liberation of cytotoxic drugs in targeted therapies. It is widely utilized in the development of antibody-drug conjugates to enhance therapeutic efficacy while minimizing off-target toxicity. -
ADC Linker
Mal-PEG2-Val-Cit-PABA-PNP is a cleavable linker designed for use in antibody-drug conjugates (ADCs). This compound features a malemide functionality for thiol conjugation, facilitating the attachment of cytotoxic agents to antibodies. Its PABA-PNP component allows for specific cleavage in the tumor microenvironment, thereby releasing the active drug and enhancing therapeutic efficacy. This linker is suitable for research applications in targeted cancer therapy development and ADC formulation studies. -
ADC Linker
SNPB is a cleavable linker specifically designed for use in antibody-drug conjugates (ADCs). This linker facilitates the targeted delivery of cytotoxic agents to tumor cells, enhancing therapeutic efficacy while minimizing off-target effects. Its unique chemical properties enable selective cleavage in the tumor microenvironment, making SNPB a valuable tool for advancing ADC research and development. -
PROTAC/ADC Linker
Amino-PEG4-CH2COOH is a PEG-based linker designed for use in the synthesis of proteolysis-targeting chimeras (PROTACs) and serves as a non-cleavable four-unit PEG linker for antibody-drug conjugates (ADCs). This compound facilitates the formation of stable conjugates, thereby enhancing the delivery of therapeutic agents to targeted cells. Its unique properties support research applications in targeted protein degradation and ADC development, contributing to advancements in cancer therapy and drug efficacy. -
ADC Linker
DBCO-PEG4-Val-Ala-PAB-PNP is a cleavable antibody-drug conjugate (ADC) linker designed for targeted delivery applications. The Val-Ala sequence enables selective cleavage by Cathepsin B, facilitating the release of the therapeutic payload. The incorporation of a PEG spacer enhances aqueous solubility, while the DBCO group is suitable for Click Chemistry reactions due to its reactivity. Additionally, the PNP moiety serves as an efficient leaving group, making this compound valuable in bioconjugation and therapeutic development. -
ADC Linker
Mal-amido-PEG10-C2-NHS ester is a non-cleavable ADC linker featuring a maleimide group and a reactive NHS ester. This compound is designed for the selective labeling of primary amines in proteins, amine-modified oligonucleotides, and other amine-containing molecules. Its versatile application in the development of antibody-drug conjugates (ADCs) facilitates targeted therapeutic strategies in chemical research. -
ADC Linker
Methyltetrazine-DBCO is a non-cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound features a DBCO group that enables strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. Additionally, the inclusion of a tetrazine moiety allows for inverse electron demand Diels-Alder reactions (iEDDA) with trans-cyclooctene (TCO) compounds. Methyltetrazine-DBCO is an essential reagent for researchers developing targeted therapies through click chemistry methodologies. -
ADC Linker
AEEA-AEEA is a non-cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs), facilitating targeted delivery of therapeutic agents. Additionally, this alkyl chain-based linker serves as a versatile component in the construction of PROTACs (proteolysis-targeting chimeras). Its stability and efficacy make it a valuable reagent for advancing cancer research and targeted protein degradation studies. -
ADC Linker
Mal-amido-PEG5-C2-NHS ester is a non-cleavable ADC linker that features a maleimide moiety and an NHS ester. This reagent effectively conjugates to primary amines (-NH2) found in proteins, amine-modified oligonucleotides, and other amine-containing biomolecules. Its design facilitates the development of antibody-drug conjugates (ADCs) for targeted therapeutics, enabling specific and stable linking of drugs to antibodies for enhanced efficacy in research applications. -
PROTAC Linkers
NH-bis-PEG2 is a non-cleavable linker featuring a two-unit polyethylene glycol (PEG) structure, primarily utilized in the development of antibody-drug conjugates (ADCs). This PEG-based linker is also applicable in the synthesis of PROTACs, facilitating targeted protein degradation. Its chemical properties allow for improved solubility and stability, making it a valuable tool in drug development and biochemical research. -
ADC Linker
Hydroxy-PEG6-acid is a PEG-based, non-cleavable linker designed for use in the synthesis of Antibody-Drug Conjugates (ADCs). This reagent enhances the solubility and stability of ADCs while maintaining the integrity of the antibody's targeting capabilities. It is suitable for various research applications, including the development of targeted cancer therapies and exploration of novel drug delivery systems. -
ADC Linker
Boc-NMe-Val-Val-Dil-Dap-OH is a versatile linker designed for use in antibody-drug conjugate (ADC) synthesis. This compound facilitates the covalent attachment of cytotoxic agents to antibodies, enhancing therapeutic efficacy while minimizing off-target effects. It is particularly useful in the development of targeted cancer therapies, enabling precise delivery of drugs to tumor cells. -
ADC Linker
NH-bis(C1-Boc) is an uncleavable linker specifically designed for use in antibody-drug conjugates (ADCs). This chemical provides stability during circulation in the bloodstream, ensuring that the drug remains attached to the antibody until it reaches the target site. Its unique characteristics facilitate targeted delivery of cytotoxic agents, enhancing therapeutic efficacy in cancer research and treatment development. -
ADC Linker
Ethyl azetidine-3-carboxylate hydrochloride functions as a non-cleavable linker for antibody-drug conjugates (ADCs). It is pivotal in the formation of stable ADCs, providing effective delivery of cytotoxic drugs to targeted cancer cells. Additionally, this compound serves as an alkyl chain-based linker in the synthesis of PROTACs, enabling selective degradation of specific proteins in research applications. -
ADC Linker
FL118-C3-O-C-amide-C-NH2 serves as an effective ADC linker, playing a crucial role in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the targeted delivery of cytotoxic agents to cancer cells, thereby enhancing therapeutic efficacy while minimizing systemic toxicity. Its application in ADC development supports research in targeted cancer therapies. -
ADC/PROTAC Linker
N-Boc-PEG7-alcohol is a PEG-based linker primarily utilized in the synthesis of PROTACs and antibody-drug conjugates (ADCs). This cleavable linker facilitates targeted drug delivery by enhancing the solubility and stability of therapeutic compounds. Its versatile applications in chemical biology make it a valuable tool for researchers aiming to develop novel targeted therapies. -
ADC/PROTAC Linker
m-PEG10-amine is a non-cleavable 10 unit polyethylene glycol (PEG) linker designed for use in the synthesis of antibody-drug conjugates (ADCs) and PROTACs (Proteolysis Targeting Chimeras). This linker enhances the solubility and stability of conjugated biomolecules, facilitating targeted delivery and improved therapeutic efficacy. It is particularly valuable in research applications focusing on ADC development and targeted protein degradation strategies. -
PROTAC Linkers
Propargyl-PEG4-Tos is a PEG-based linker specifically designed for the synthesis of PROTACs (proteolysis-targeting chimeras). It serves as a cleavable linker in antibody-drug conjugates (ADCs), facilitating targeted delivery of therapeutic agents. This compound features an alkyne group that enables copper-catalyzed azide-alkyne cycloaddition (CuAAc), allowing for efficient conjugation with azide-containing molecules. Its versatile applications make it a valuable tool in chemical biology and drug development research. -
ADC/PROTAC Linker
N-Boc-PEG6-alcohol is a PEG-based linker designed for antibody-drug conjugate (ADC) and PROTAC applications. This cleavable linker facilitates the synthesis of PROTACs, allowing for targeted degradation of specific proteins. Its unique structure provides enhanced solubility and stability, making it suitable for various biochemical studies focused on targeted therapies and protein regulation. -
ADC Linker
trans-Sulfo-SMCC is a non-cleavable crosslinker designed for antibody-drug conjugates (ADCs), known for its membrane permeability. This reagent facilitates stable linkage between antibodies and cytotoxic agents, enhancing therapeutic efficacy while ensuring targeted delivery. It is ideal for research applications focused on ADC development and the investigation of targeted drug delivery systems. -
ADC Linker
PPC-NB is a glutathione-cleavable linker designed for antibody-drug conjugates (ADCs). This compound facilitates the selective release of cytotoxic agents in targeted cancer therapy, enhancing the therapeutic index of ADCs. Its unique properties make it suitable for research applications focused on improving drug delivery systems and developing novel therapeutic strategies in cancer treatment. -
ADC Linker
Mal-PEG1-Val-Cit-PAB-PNP is a cleavable linker designed for the construction of antibody-drug conjugates (ADCs). This compound features a polyethylene glycol (PEG) spacer, allowing for flexible and stable conjugation to antibodies. It is specifically engineered to facilitate the release of cytotoxic agents in targeted therapy applications, making it valuable in cancer research and drug development. -
ADC Linker
PC SPDP-NHS carbonate ester is a cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the selective conjugation of therapeutic agents to antibodies, allowing for targeted drug delivery. Its functionality promotes the release of the drug in the desired cellular environment, enhancing therapeutic efficacy. Researchers utilize this linker in studies focused on improving the specificity and effectiveness of ADC-based therapies. -
ADC Linker
SC209 intermediate-2 is an ADC linker designed for use in antibody-drug conjugate (ADC) synthesis. This compound serves as an essential intermediate for the cytotoxin SC209, enabling targeted delivery of therapeutic agents to cancer cells. SC209 intermediate-2 plays a crucial role in enhancing the efficacy of ADCs in research applications focused on cancer treatment and drug development. -
ADC Linker
BCN-linker-DXd 2 is a specialized ADC (antibody-drug conjugate) linker designed for targeted delivery of cytotoxic agents to cancer cells. This compound facilitates the conjugation of drugs to antibodies, enhancing specificity and reducing off-target effects in cancer therapy. It is applicable in research focused on ADC development and optimization for improved therapeutic efficacy against various types of tumors. -
Anti-Nectin-4 ADC Linker
Mal-PEG8-Val-Ala-PAB-Exatecan is an anti-Nectin-4 antibody-drug conjugate (ADC) linker designed to facilitate targeted delivery of chemotherapeutic agents. This compound enables precise conjugation to Nectin-4 polypeptides, allowing for enhanced therapeutic efficacy in cancer research applications. Its unique structure promotes stability and release characteristics, making it suitable for studying the effects of ADCs in various tumor models. -
ADC Linker
SuO-Glu-Val-Cit-PAB-MMAE is a cleavable antibody-drug conjugate (ADC) linker that combines SuO-Glu-Val-Cit-PAB with the potent tubulin inhibitor MMAE. This compound enables targeted delivery of MMAE via ADC technology, facilitating selective cytotoxicity in cancer research. SuO-Glu-Val-Cit-PAB-MMAE is suitable for the synthesis of ADCs, providing a strategic approach to enhance therapeutic efficacy while minimizing off-target effects. -
Cleavable ADC Linker
Amino-PEG4-Val-Cit-PAB-MMAE is a cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates selective drug delivery by connecting antibodies to the cytotoxic agent MMAE, enhancing therapeutic efficacy while minimizing off-target effects. Its PEG4 moiety ensures improved solubility and stability, making it suitable for research applications in cancer therapy and targeted delivery systems. -
ADC/PROTAC Linkers
Glucocorticoid receptor agonist-1 phosphate(2,6-difluoro) Ala-Ala-Br serves as a versatile drug-linker conjugate for antibody-drug conjugate (ADC) applications. This reagent enables the synthesis of conjugates targeting the CD40 antigen, facilitating the development of targeted therapies. Its unique structure supports the design of PROTACs and other innovative bio-conjugates, contributing to advances in cancer research and immunotherapy. -
ADC Linker
OH-Glu-Val-Cit-PAB-MMAE is a cleavable antibody-drug conjugate (ADC) linker that incorporates a potent tubulin inhibitor, MMAE. This compound is designed for the synthesis of ADCs, facilitating targeted delivery of cytotoxic agents to cancer cells. Its unique structure allows for selective release of MMAE, enhancing therapeutic efficacy while minimizing off-target effects. This reagent is valuable for researchers developing novel ADCs in the field of cancer treatment. -
ADC Linker
IM-2 is a potent ADC linker designed for the synthesis of antibody-drug conjugates (ADCs). It facilitates the efficient conjugation of cytotoxic agents to antibodies, enhancing targeted delivery to cancer cells while minimizing systemic toxicity. This reagent is ideal for research applications focused on developing novel therapeutic modalities in oncology. -
ADC Linker-payload
Exatecan-mpGNNG is a linker-payload component designed for use in antibody-drug conjugates (ADCs). It integrates Exatecan, a highly effective inhibitor of topoisomerase I, facilitating targeted delivery of therapeutic agents to cancer cells. This compound is particularly relevant for research applications focusing on ADC development and the evaluation of antitumor efficacy. -
MMAF-ADC Linker
Fmoc-Val-Cit-PAB-MMAF-OtBu is a linker compound designed for the conjugation of MMAF (monomethyl auristatin F) to antibodies, facilitating the formation of antibody-drug conjugates (ADCs). This versatile linker allows for the selective delivery of the cytotoxic agent to tumor cells, enhancing anti-tumor efficacy while minimizing systemic toxicity. Fmoc-Val-Cit-PAB-MMAF-OtBu is suitable for research applications in ADC development and cancer therapeutics. -
ADC Linker
MC-VC-PAB-Tubulysin M is a synthetic antibody-drug conjugate (ADC) linker that combines the potent tubulin polymerization inhibitor, Tubulysin M, with the cleavable linker MC-vc-PAB. This conjugate targets and disrupts microtubule dynamics, offering potential for selective cytotoxicity in cancer treatment. It is primarily utilized in the development of ADCs to enhance therapeutic efficacy while minimizing off-target effects in various cancer research applications. -
ADC Linker
diSPhMC-Asn-Pro-Val-PABC-MMAE is an effective ADC linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the selective delivery of therapeutic agents to target cells, enhancing the efficacy of cancer treatment while minimizing systemic toxicity. It is suitable for applications in targeted therapy research and the development of novel ADC formulations. -
ADC Linker
Asn-Pro-Val-PABC-MMAE TFA is an effective ADC linker designed for the development of antibody-drug conjugates (ADCs). This compound facilitates the conjugation of cytotoxic drugs to antibodies, enhancing targeted delivery and therapeutic efficacy. It is a valuable tool for researchers focused on developing novel ADC therapies for cancer treatment and other diseases. -
ADC Linker
DeBoc-Cabazitaxel serves as a versatile ADC linker, facilitating the conjugation of antibodies to cytotoxic agents for targeted therapy. This compound enhances the efficacy of antibody-drug conjugates (ADCs) by enabling selective delivery to tumor cells while minimizing off-target effects. It is particularly valuable in the development of novel cancer therapies, supporting research in targeted anti-tumor strategies. -
ADC linker
Dap-NE is an intermediate reagent specifically designed for use in the synthesis of antibody-drug conjugates (ADCs), particularly the cytotoxic agent Monomethyl auristatin E. Its role as a linker plays a critical part in ensuring the efficient delivery of therapeutic agents to targeted cells, enhancing the efficacy of the ADC. This compound is essential for researchers investigating novel ADC formulations and their applications in cancer therapeutics.
